A number of recent articles discuss the growing epidemic of drug-resistant strains of bacteria in the U.S. and worldwide. EndogenX is in the process of making available a neutralizing compound allowing the antibiotic drugs Vancomycin and Cephalosporin to be combined without causing an adverse reaction. This creates a powerful broad spectrum super antibiotic. Due to its novel breakthrough, patents are filed internationally for this biotechnology.

	Research		Development		Market
ENDG0010 Sinus Infections
ENDG0020 Ear Infections
ENDG1010 Pneumonia
ENDG1020 Meningitis
ENDG1030 Cystic Fibrosis
ENDG1040 MRSA
ENDG1050 Mixed Bacterial